Literature DB >> 24887450

Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats.

Jenny L Wiley1, Timothy W Lefever2, Ricardo A Cortes2, Julie A Marusich2.   

Abstract

Synthetic indole-derived cannabinoids, originally developed to probe cannabinoid CB1 and CB2 receptors, have become widely abused for their marijuana-like intoxicating properties. The present study examined the effects of indole-derived cannabinoids in rats trained to discriminate Δ(9)-tetrahydrocannabinol (Δ(9)-THC) from vehicle. In addition, the effects of Δ(9)-THC in rats trained to discriminate JWH-018 from vehicle were assessed. Adult male Sprague-Dawley rats were trained to discriminate 3mg/kg Δ(9)-THC or 0.3mg/kg JWH-018 from vehicle. JWH-018, JWH-073, and JWH-210 fully substituted in Δ(9)-THC-trained rats and Δ(9)-THC substituted in JWH-018-trained rats. In contrast, JWH-320, an indole-derived cannabinoid without affinity for CB1 receptors, failed to substitute for Δ(9)-THC. Pre-treatment with 1mg/kg rimonabant significantly reduced responding on the JWH-018-associated lever in JWH-018-trained rats. These results support the conclusion that the interoceptive effects of Δ(9)-THC and synthetic indole-derived cannabinoids show a large degree of overlap, which is predictive of their use for their marijuana-like intoxicating properties. Characterization of the extent of pharmacological differences among structural classes of cannabinoids, and determination of their mechanisms remain important goals.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Discriminative stimulus; JWH-018; JWH-073; JWH-210; Synthetic cannabinoids; Δ(9)-tetrahydrocannabinol

Mesh:

Substances:

Year:  2014        PMID: 24887450      PMCID: PMC4150816          DOI: 10.1016/j.pbb.2014.05.016

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  44 in total

Review 1.  Indoles and related compounds as cannabinoid ligands.

Authors:  Clementina Manera; Tiziano Tuccinardi; Adriano Martinelli
Journal:  Mini Rev Med Chem       Date:  2008-04       Impact factor: 3.862

2.  Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Authors:  Lisa K Brents; Sarah M Zimmerman; Amanda R Saffell; Paul L Prather; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2013-06-25       Impact factor: 4.030

3.  Prediction and Prevention of Prescription Drug Abuse: Role of Preclinical Assessment of Substance Abuse Liability.

Authors:  Julie A Marusich; Timothy W Lefever; Scott P Novak; Bruce E Blough; Jenny L Wiley
Journal:  Methods Rep RTI Press       Date:  2013-07

4.  1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Authors:  Jenny L Wiley; Julie A Marusich; Billy R Martin; John W Huffman
Journal:  Drug Alcohol Depend       Date:  2011-11-27       Impact factor: 4.492

5.  Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A.

Authors:  A. Pério; M. Rinaldi-Carmona; J. Maruani; F. Barth; G. Le Fur; P. Soubrié
Journal:  Behav Pharmacol       Date:  1996-01       Impact factor: 2.293

6.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

7.  URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products.

Authors:  Nahoko Uchiyama; Maiko Kawamura; Ruri Kikura-Hanajiri; Yukihiro Goda
Journal:  Forensic Sci Int       Date:  2012-10-09       Impact factor: 2.395

8.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

Authors:  D R Compton; L H Gold; S J Ward; R L Balster; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

9.  Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.

Authors:  Robert E Vann; Jonathan A Warner; Kristen Bushell; John W Huffman; Billy R Martin; Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2009-05-23       Impact factor: 4.432

10.  Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.

Authors:  J L Wiley; R L Barrett; J Lowe; R L Balster; B R Martin
Journal:  Neuropharmacology       Date:  1995-06       Impact factor: 5.250

View more
  23 in total

1.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

2.  Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Behav Pharmacol       Date:  2014-12       Impact factor: 2.293

Review 3.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 4.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

5.  Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Behav Pharmacol       Date:  2015-08       Impact factor: 2.293

6.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

7.  Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Authors:  Travis W Grim; Kimberly L Samano; Bogna Ignatowska-Jankowska; Qing Tao; Laura J Sim-Selly; Dana E Selley; Laura E Wise; Alphonse Poklis; Aron H Lichtman
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

8.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

9.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

10.  Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018.

Authors:  Benjamin M Ford; Christian V Cabanlong; Sherrica Tai; Lirit N Franks; Narsimha R Penthala; Peter A Crooks; Paul L Prather; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2019-03-04       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.